Opko Health (OPK) Research & Development (2010 - 2026)

Opko Health has reported Research & Development for 17 years, with the latest figure at $29.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 5.32% year-over-year to $29.2 million; the trailing twelve-month figure through Mar 2026 stood at $122.4 million (up 15.87% YoY), and the FY2025 full-year result was $124.0 million, up 17.89% from the prior year.
• Research & Development for Q1 2026 stood at $29.2 million, down from $32.8 million in the prior quarter.
• The five-year high for Research & Development was $32.8 million in Q4 2025, with the low at $17.3 million in Q2 2022.
• Historically, Research & Development has averaged $24.5 million across 5 years, with a median of $23.0 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development surged 78.05% — and 2024, when it slumped 32.72%.
• Opko Health's Research & Development stood at $19.5 million in 2022, then fell by 0.69% to $19.4 million in 2023, then soared by 48.34% to $28.8 million in 2024, then rose by 13.91% to $32.8 million in 2025, then retreated by 10.9% to $29.2 million in 2026.
• The last three Research & Development figures came in at $29.2 million (Q1 2026), $32.8 million (Q4 2025), and $30.1 million (Q3 2025), per Business Quant data.